(firstQuint)Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma.

 Preliminary data suggest intralesional rituximab is able to revert resistance to systemic rituximab in patients with CD20+ indolent lymphoma of the conjunctiva, and the addition of autologous serum seems to exhibit a synergistic effect on tumor regression.

 These two main aspects will be assessed in this trial.

.

 Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma@highlight

Phase II, monocentric, open label study to assess safety and activity of intralesional Rituximab for the treatment of indolent CD20+ lymphoma of conjunctiva.

